Urol. praxi. 2023;24(2):72-79 | DOI: 10.36290/uro.2023.043

Testosterone deficiency in adulthood, diagnosis and possibilities of therapeutic substitution

doc. MUDr. Taťána Šrámková, CSc.
Klinika komplexní onkologické péče, Masarykův onkologický ústav v Brně
Urologická klinika 1. LF a VFN v Praze
Klinika traumatologie LF MU v Brně

Late-onset hypogonadism in adulthood represents a significant health problem because, based on the association of low testosterone levels with diabetes, cardiovascular disease and osteoporosis, it leads to reduced length and quality of life. Hypogonadal men die earlier than men with a sufficient supply of androgens, and cardiovascular disease and diabetes contribute significantly to this. The diagnosis of testosterone deficiency requires the presence of clinical manifestations and laboratory confirmation of its abnormal level. If the diagnosis is confirmed, lifestyle modification and injectable, oral or transdermal substitutions are recommended. The choice of the form of androgen therapy should be made on the basis of patient preference, pharmacokinetics, cost of treatment with achieving a testosterone level at half the normal level according to the recommendations of European Association of Urology. The patient must be regularly checked up by performing a physical examination including prostate examination and comprehensive serum analysis.. The benefit of the treatment for the patient is the achievement of physiological levels of testosterone, improvement of sexual functions, muscle strength and mass, increase of energy, bone density, feeling of well-being and improvement of cardiovascular morbidity.

Keywords: testosterone, late-onset adult hypogonadism, androgen therapy, transdermal testosterone.

Accepted: June 13, 2023; Published: June 15, 2023  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Šrámková T. Testosterone deficiency in adulthood, diagnosis and possibilities of therapeutic substitution. Urol. praxi. 2023;24(2):72-79. doi: 10.36290/uro.2023.043.
Download citation

References

  1. Fryšák Z, Karásek D, Halenka M. Hypogonadismus mužů - příčiny, diagnostika, léčba. Urol praxi. 2010;11(2):75-77.
  2. Stárka L. Mužský hypogonadismus a civilizační onemocnění. Čas Lék Čes. 2012;151(2):69-72.
  3. Salonia A, Bettocchi C, Carvalho J, et al. EAU Guidelines on Sexual and Reproductive Health [online]. Available from: https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAUGuidelines-on-Sexual-and-Reproductive-Health-2022_2022-03-29-084141_megw.pdf;https://uroweb.org/guidelines/sexual-and-reproductive-health/summary-of-changes/2022. EAU-Guidelines-on-Sexual-and-Reproductive-Health-2023.pdf (d56bochluxqnz.cloudfront.net).
  4. Stárka L, Dušková M, Hill M. Hypogonadismus obézních mužů. EAU-Guidelines-on-Sexual-and-Reproductive-Health-2023.pdf (d56bochluxqnz.cloudfront.net). Vnitř Lék. 2020;66(8):e24-e27. Go to original source...
  5. Wang CH, Jackson G, Jones TH, et al. Low testosterone associated with obesity and the metabolic syndrome contributes to sexual dysfunction and cardiovascular disease risk in men with type 2 diabetes. Diabetes Care. 2011;34(7):1669-1675. Go to original source... Go to PubMed...
  6. Grossmann M, Matsumoto AM. A perspective on middle-aged and older men with functional hypogonadism: focus on holistic management. J Clin Endocrinol Metab. 2017;102(3):1067-1075. Go to original source... Go to PubMed...
  7. Fukui M, Tanaka M, Toda H, et al. Andropausal symptoms in men with Type 2 diabetes. Diabet Med. 2012;29(8):1036-1042. Go to original source... Go to PubMed...
  8. Zitzmann M, Faber S, Nieschlag, E. Association of specific symptoms and metabolit risks with serum testosterone in older men. J Clin Endocrionol Metab. 2006;91,1(11):4335-4343. Go to original source... Go to PubMed...
  9. Araujo AB, Dixon JM, Suarez EA, et al. Endogenous testosterone and mortality in men: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2011;96(10):3007-3019. Go to original source... Go to PubMed...
  10. Haring R, Volzke H, Steveling A, et al. Low serum testosterone level are associated with increased risk of mortality in a population based kohort of men aged 20-79. Eur Heart J. 2010;31(12):1494-1501. Go to original source... Go to PubMed...
  11. Heinemann LAJ, Zimmermann T, Vermeulen A, et al. A New 'Aging Male's Symptoms'(AMS) Rating Scale. Aging Male. 1999;2:105-114. Go to original source...
  12. Moore C, Huebler D, Zimmermann T, et al. The Aging Males Symptom Scale (AMS) as outcome measure for treatment of androgen deficiency. Eur Urol. 2004;46(1):80-87. Go to original source... Go to PubMed...
  13. https://www.sukl.cz/modules/medication/search.php.
  14. Lanser L, Burkert FR, Thommes L, et al. Testosterone deficiency is a risk factor for severe COVID-19. Front Endocrinol (Lausanne). 2021;12:694083. Go to original source... Go to PubMed...
  15. Salonia A, Pontillo M, Capogrosso P, et al. Testosterone in males with COVID-19: A 7-month cohort study. Andrology. 2022;10(1):34-41. Go to original source... Go to PubMed...
  16. Vena W, Pizzocaro A, Maida G, et al. Low testosterone predicts hypoxemic respirátory insufficiency and mortality in patients with COVID-19 disease: another piece in the COVID puzzle. J Endocrinol Invest. 2022;45(4):753-762. Go to original source... Go to PubMed...
  17. Nassau DE, Best JC, Kresch E, et al. Impact of the SARS-CoV-2 virus on male reproductive health. BJU Int. 2022; 129(2):143-150. Go to original source... Go to PubMed...
  18. Šrámková T. Mužské stárnutí z pohledu sexuologa. Praha: Grada-Publishing a. s., 2023;200 s.




Urology for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.